knowledge -WSS

knowledge

author：entertainment 2025-09-30 16:23:48 - browse：2

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： CDC's new outbreak response network to include Northeastern

focus

WSS

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Drug for rare kidney disease narrowly misses mark in clinical trial

Travel bans should be based on evidence, not politics or fear

Emergency workers more likely to restrain Black patients: study

Lasker Awards 2023: Winners in biomedical research

Lasker Awards 2023: Winners in biomedical research

entertainment

knowledge

focus

After affirmative action ruling, medical educators look to 'holistic review'

STAT Virtual Event: Putting AI to the Test

Apple is now the first public company to be valued at $3 trillion

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

New air purifier tech could be key to improving indoor air quality

CommonSpirit Health keeps growing, even as it loses money

In age of alternative facts, a scholarly course on calling out crap

‘The Bear’ and hospitality in hospitals

Duchenne breakthrough therapy leaves behind pioneering families

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

focus

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Biotech stock slump in 2023: awaiting the turnaround

Wegovy cuts risk of cardiovascular events by 20%, study finds

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Astronauts get first look at the spacecraft that will fly them around the moon

In venture capital firm's success, lessons for turning crisis into profit

explore

leisure time

focus

explore